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Molecular and flow cytometric analysis of the Vb repertoire for clonality
assessment in mature TCRab T-cell proliferations
Anton W. Langerak, Rene´ van den Beemd, Ingrid L. M. Wolvers-Tettero, Patrick P. C. Boor, Ellen G. van Lochem,
Herbert Hooijkaas, and Jacques J. M. van Dongen
Clonality assessment through Southern
blot (SB) analysis of TCRB genes or poly-
merase chain reaction (PCR) analysis of
TCRG genes is important for diagnosing
suspect mature T-cell proliferations.
Clonality assessment through reverse
transcription (RT)–PCR analysis of Vb-Cb
transcripts and flow cytometry with a Vb
antibody panel covering more than 65%
of Vb domains was validated using 28
SB-defined clonal T-cell receptor
(TCR)ab1 T-ALL samples and T-cell lines.
Next, the diagnostic applicability of the Vb
RT-PCR and flow cytometric clonality as-
says was studied in 47 mature T-cell
proliferations. Clonal Vb-Cb RT-PCR prod-
ucts were detected in all 47 samples,
whereas single Vb domain usage was
found in 31 (66%) of 47 patients. The
suspect leukemic cell populations in the
other 16 patients showed a complete lack
of Vb monoclonal antibody reactivity that
was confirmed by molecular data show-
ing the usage of Vb gene segments not
covered by the applied Vb monoclonal
antibodies. Nevertheless, this could be
considered indirect evidence for the
“clonal” character of these cells. Remark-
ably, RT-PCR revealed an oligoclonal pat-
tern in addition to dominant Vb-Cb prod-
ucts and single Vb domain expression in
many T-LGL proliferations, providing fur-
ther evidence for the hypothesis raised
earlier that T-LGL derive from polyclonal
and oligoclonal proliferations of antigen-
activated cytotoxic T cells. It is concluded
that molecular Vb analysis serves to
assess clonality in suspect T-cell prolif-
erations. However, the faster and
cheaper Vb antibody studies can be
used as a powerful screening method
for the detection of single Vb domain
expression, followed by molecular stud-
ies in patients with more than 20% single
Vb domain expression or large suspect
T-cell populations (more than 50%-60%)
without Vb reactivity. (Blood. 2001;98:
165-173)
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Introduction
In striking contrast to the straightforward clonality assessment in
most mature B-cell proliferations through single immunoglobulin
light chain expression, clonality assessment in suspect T-cell
proliferation is not possible through routine immunologic marker
analysis. For instance, the T-cell receptor (TCR) expression pattern
(TCRab or TCRgd), the unusual CD4/CD8 expression pattern, or
the so-called loss of T-cell markers is insufficient to establish the
malignant (clonal) character of a suspect T-cell proliferation.1 As a
consequence, molecular analysis of TCR gene rearrangements has
developed as an important tool for clonality assessment in such
proliferations. As with normal T cells in various differentiation
stages, TCR genes are rearranged in most T-cell malignancies.2 The
presence or absence of identically (clonally) rearranged TCR genes
is therefore helpful for distinguishing between (mono)clonal and
polyclonal (reactive) T-cell proliferations, respectively.
Southern blot (SB) analysis is the classical diagnostic method
for clonality assessment. It is highly reliable and in principle can
detect every clonal TCR gene rearrangement, provided that opti-
mally positioned probes and appropriate restriction enzymes are
used.3-6 Nevertheless, several drawbacks limit the routine applica-
tion of SB analysis in diagnostic laboratories. SB is labor intensive
and time consuming, especially when sequential hybridizations are
required; furthermore, relatively large amounts of high-quality
DNA are needed for reliable results, which precludes its application
on paraffin-embedded samples. Despite these disadvantages, SB-
based detection of clonal TCR rearrangements is the gold standard
technique by which to validate other methods for clonality
assessment in suspect T-cell proliferations. Today, polymerase
chain reaction (PCR) analysis of TCR gamma (TCRG) genes is
most widely applied; the relatively restricted combinatorial reper-
toire of TCRG genes limits the number of required PCR primers.
However, this limited repertoire also results in high background
amplification of similar rearrangements in normal T cells, thereby
reducing the sensitivity of the assay. Other approaches focus on
analysis of TCRB genes or TCRB gene products (RNA, proteins, or
both), exploiting the high diversity in Vb gene usage for clonality
studies. PCR-based analysis of the Vb repertoire mostly concerns
reverse transcription (RT)–PCR amplification of Vb-Cb transcripts
to limit the number of primers needed to cover the many involved
gene segments.7 With the recent availability of a panel of Vb
antibodies that covers more than 65% of all Vb domains,8 flow
cytometric analysis of the Vb repertoire now promises to be a
relevant alternative approach for molecular clonality studies.9,10
This is especially true because reference values have been
determined in healthy controls for the available individual Vb
antibodies.10
Here we present 2 different approaches of Vb repertoire
analysis: Vb-Cb RT-PCR and flow cytometry with Vb antibodies.
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After validation on SB-defined clonal TCRab1 T-cell acute
lymphoblastic leukemia (T-ALL) samples and a series of T-cell
lines, the diagnostic applicability of the 2 methods was tested in a
series of 47 mature T-cell proliferations. The feasibility and
applications of both Vb clonality assays are discussed.
Patients, materials, and methods
Patients, cell samples, and cell lines
Peripheral blood (PB) samples were collected from patients (n 5 47)
showing persistent mature TCRab1 T-cell proliferation, including T-cell
chronic lymphocytic leukemia (T-CLL), T-cell large granular lymphocyte
leukemia (T-LGL), T-cell non-Hodgkin lymphoma (T-NHL), T-cell prolym-
phocytic leukemia (T-PLL), and mycosis fungoides/Se´zary syndrome
(MF/SS). Mononuclear cells (MNCs) were isolated by Ficoll-Hypaque
(density, 1.077 g/mL; Pharmacia, Uppsala, Sweden) density centrifugation
and used for immunophenotyping and Vb analysis and for DNA and
RNA isolation.
TCRab1 or cytoplasmic TCRb1 (CyTCRb1) T-cell lines (n 5 12) and
MNC fractions of PB or bone marrow (BM) samples from patients with
TCRab1 T-ALL (n 5 16) were used as reference samples.
Immunophenotyping and analysis of Vb domains
of expressed TCRb chains
MNCs were analyzed for cell membrane expression of T-cell markers and
for expression of the HLA-DR antigen (L243), cytoplasmic TCRb (bF1),
TCRab (BMA031) and TCRgd (11F2) with the following monoclonal
antibodies (mAbs): CD2 (Leu-5b), CD3 (Leu-4), CD4 (Leu-3a), CD5
(Leu-1), CD7 (3A1), CD8 (Leu-2a), CD16 (Leu-11c), CD56 (Leu-19), and
CD57 (Leu-7). The mAbs of the Leu series, as well as L243 and 11F2, were
obtained from Becton Dickinson (San Jose, CA), the 3A1 hybridoma was
obtained from ATCC (Rockville, MD), bF1 from T-cell Sciences (Need-
ham, MA), and BMA031 from Immunotech (Marseilles, France). Immuno-
fluorescence stainings were performed as described and evaluated on a
FACScan flow cytometer using CellQuest software (Becton Dickinson).10
The samples were studied in more detail for Vb domain expression
using a panel of carefully selected Vb mAbs (Table 1).10 Data acquisition
and analysis of the Vb immunofluorescence stainings in T-ALL samples
and T-cell lines were performed in double stainings using unconjugated Vb
mAbs, followed by incubation with fluorescein isothiocyanate (FITC)-
conjugated goat antimouse immunoglobulin (CLB, Amsterdam, The Neth-
erlands) and subsequently normal mouse serum to block free antigen
binding sites of the second-step reagent, after which CD3-PE (Leu-4) was
added.10 In T-cell lines with cytoplasmic TCRb expression (bF1 reactivity),
cells were permeabilized before Vb staining. For the mature TCRab1
T-cell proliferations, the Vb mAbs were used in combination with
CD3-PerCP (Leu-4) and occasionally CD4-PE (Leu-3a) or CD8-PE (Leu-
2a) to further define the immunophenotype of the T cells.10 The Vb
antibodies were from Immunotech (Marseilles, France), T-cell Sciences
(Needham, MA), and T-cell Diagnostics (Cambridge, MA) (Table 1 for the
origin of the Vb antibodies). In addition, several samples were studied by
means of 6 mixtures of clustered Vb antibodies as a fast and easy method
for the identification of single Vb domain expression, as described by Van
den Beemd et al.10 These 6 mixtures consisted of: MIX1, Vb3 (CH92) and
Vb5.1 (IMMU157); MIX2, Vb8.1/8.2 (56C5.2) Vb12.2 (VER2.32), and
Vb17 (E17.5F3); MIX3, Vb2 (MPB2/D5), Vb16 (TAMAYA1.2), and
Vb23 (HUT78.7/AF23); MIX4, Vb6.1 (CRI304.3), Vb7.1 (Zoe´), Vb9.1
(FIN9), Vb11.1 (C21), and Vb14 (CAS1.1.3); MIX5, Vb13.6 (JU74.3),
Vb18 (BA62.6), Vb20 (ELL1.4), Vb21.3 (IG125), and Vb22 (IMMU546);
and MIX6, Vb5.2/5.3 (4H11), Vb6.7 (OT145), and Vb13.1/13.3 (BAM13).10
DNA and RNA isolation and cDNA synthesis
DNA was isolated from frozen MNCs and cell lines as described earlier.3
Total RNA was isolated from all samples using RNAzol (Tel-Test,
Friendswood, TX). After oligo dT annealing for 3 minutes at 85°C, 2 mg
total RNA was subsequently reverse transcribed in 40 mL volumes for 1
hour at 41°C using Superscript II RT enzyme (Life Technologies, Paisley,
United Kingdom) in the presence of dNTPs and RNAguard (Amersham
Pharmacia Biotech, Uppsala, Sweden).
Southern blot analysis
Southern blot (SB) analysis of the TCRB genes was performed as
described.3 The 32P-labeled TCRBJ1, TCRBJ2, and TCRBC genomic DNA
probes (DAKO, Carpinteria, CA) were used in subsequent hybridizations of
EcoRI- and HindIII-digested DNA to determine the rearrangement status of
the T-cell lines and patient samples.5
PCR amplification
Oligonucleotide primers used for amplification of Vb-Cb transcripts are
given in Table 2. Most Vb family-specific primers were adapted from those
published by Gorski et al,7 but several primers were added to maximize
recognition of Vb gene segments within a given family and to minimize
cross-annealing to other Vb gene families at the 39 primer ends. The Cb
primer was also adapted from Gorski et al.7 The quality of the studied
cDNA samples was determined through RT-PCR analysis of the ubiqui-
tously expressed ABL gene. PCR amplification of the TCRB genes of the
cDNA samples was performed in multiple tubes (n 5 31), each containing
one of the Vb family primers and the Cb primer (Table 2). Reactions were
performed in 20 mL volumes, containing one fortieth (1 mL) of the cDNA
reaction mixture, 2.5 pmol Vb family primer, 2.5 pmol Cb primer, 0.2 mM
dNTPs, 1.5 mM MgCl2, and 0.2 U AmpliTaq DNA polymerase in reaction
buffer II (Applied Biosystems, Foster City, CA). PCR reaction conditions
for the Perkin-Elmer 480 thermal cycler (Applied Biosystems) were initial
denaturation of 3 minutes at 94°C, followed by 35 to 40 cycles of 1 minute
at 94°C, 1 minute at 60°C, 2 minutes at 72°C, and a final extension step of
10 minutes at 72°C.
Heteroduplex analysis
After amplification, half (10 mL) the PCR mixtures were loaded on 1%
agarose gels to evaluate PCR product formation with the various Vb-Cb
Table 1. Vb antibodies and their reactivity in healthy controls
Vb antibody
specificity mAb clone Manufacturer
% Vb expression per
CD3/TCRab cells*
Median
(p10-p90)
Upper
limit
(3 SD)
Vb1 BL37.2 Immunotech 4.1 (3.4-5.9) 8.9
Vb2 MPB2/D5 Immunotech 8.6 (6.2-11.2) 14.0
Vb3 CH92 Immunotech 4.5 (1.5-8.5) 12.5
Vb5.1 IMMU157 Immunotech 6.5 (4.0-8.7) 12.3
Vb5.2/5.3 4H11 T-cell Sciences 3.2 (2.1-3.8) 5.1
Vb6.1 CRI304.3 Immunotech 1.3 (0.5-2.8) 4.1
Vb6.7 OT145 T-cell Diagnostics 3.0 (0.5-5.5) 8.2
Vb7.1 Zoe´ Immunotech 2.8 (1.6-4.6) 6.4
Vb8.1/8.2 56C5.2 Immunotech 5.0 (3.5-6.5) 8.6
Vb9.1 FIN9 Immunotech 3.2 (2.1-4.7) 7.2
Vb11.1 C21 Immunotech 0.8 (0.5-1.4) 2.2
Vb12.2 VER2.32 Immunotech 2.4 (1.3-3.6) 6.5
Vb13.1/13.3 BAM13 T-cell Sciences 5.9 (4.3-10.8) 20.5
Vb13.6 JU74.3 Immunotech 2.1 (1.5-3.0) 5.7
Vb14 CAS1.1.3 Immunotech 3.7 (2.1-8.6) 16.9
Vb16 TAMAYA1.2 Immunotech 1.3 (1.0-1.7) 2.2
Vb17 E17.5F3 Immunotech 5.2 (3.8-6.5) 8.9
Vb18 BA62.6 Immunotech 0.5 (0.5-1.5) 2.1
Vb20 ELL1.4 Immunotech 2.4 (1.1-4.1) 5.9
Vb21.3 IG125 Immunotech 2.8 (1.8-4.2) 6.9
Vb22 IMMU546 Immunotech 4.0 (0.6-5.3) 11.1
Vb23 HUT78.7/AF23 Immunotech 1.3 (0.5-2.5) 3.8
*Reference values are derived from Van den Beemd et al.10
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primer combinations. PCR products were visualized by ethidium
bromide using UV light. The other 10 mL PCR reaction mixture was
subjected to heteroduplex analysis to discriminate between monoclonal
and polyclonal PCR products.11 In short, heteroduplex analysis con-
sisted of 59 denaturation at 94°C immediately followed by 609 renatur-
ation at 4°C before electrophoresis on 6% nondenaturing polyacryl-
amide gels (polyacrylamide:bisacrylamide 29:1) in 0.53 TBE buffer.11
Ethidium bromide-stained homoduplex or heteroduplex PCR products
were visualized with UV light.
Sequencing
If heteroduplex analysis showed PCR products to be clonal, the
homoduplexes were excised from the gel and eluted as described.12
Eluted products were either directly sequenced or reamplified in a
second-step PCR reaction using the same primers as in the initial
reaction. Sequencing was performed on the ABI377 fluorescence
sequencer (Applied Biosystems) using the dye terminator cycle sequenc-
ing kit and AmpliTaq FS (Applied Biosystems).12 Assignment of Vb,
Db, Jb, and Cb gene segments and reading frames of the involved TCRB
gene rearrangements was performed as described.13,14
Results
Molecular and flow cytometric Vb analysis in T-cell lines
To study the feasibility of Vb analysis in clonal T-cell popula-
tions, we used a panel of 12 T-cell lines (Table 3). Although only
4 of these cell lines showed TCRab membrane expression, all
had cytoplasmic expression of TCRb chains. SB analysis
revealed clonal TCRB gene rearrangements in all cell lines. In 6
of the T-cell lines, 2 clear Vb-Cb RT-PCR products were found,
and in the other 6 only one was found (Table 3). The Vb-Cb
products of the various cell lines contained V gene segments
from many distinct Vb families, with a slight predominance of
Vb2-Cb products (n 5 3). Remarkably, in most identified
transcripts, Jb2 region gene segments were used, which fits with
the predominance of Vb-Jb2 gene rearrangements in immature
T-cell malignancies.5 Further sequencing of the clonal products
revealed that all except one of the cell lines showed a single
in-frame Vb-Cb RT-PCR product (Table 3). In cell line KT-1,
both an in-frame Vb18-Cb and an in-frame Vb15-Cb transcript
were found, whereas in the other 5 cell lines with 2 clonal
Vb-Cb products only one appeared in-frame.
Flow cytometric Vb analysis using a panel of Vb family
antibodies (Table 1) showed reactivity with one of the Vb mAbs
from the panel in 10 of the 12 cell lines, with a specificity profile
that completely correlated with the presence of the identified
in-frame Vb-Cb transcript (Table 3). Cell line KT-1, having
in-frame Vb15-Cb and Vb18-Cb transcripts, reacted with the
Vb18 antibody. However, double (membrane or cytoplasmic) Vb
expression could not be confirmed or excluded in this cell line
because Vb15-specific antibodies were not available. In 2 cell
lines, no reactivity was observed with any of the Vb mAbs of the
panel, despite cytoplasmic TCRb chain (bF1 mAb) detection. In
the RPMI 8402 cell line, this could easily be explained by the lack
of a Vb24-specific antibody, but for the DND-41 cell line the
appropriate Vb18 antibody was present in the panel. The fact that
DND-41 expresses a bd TCR rather than an ab TCR might,
however, hamper proper detection of the recognized epitope of the
Vb18 domain expressed in this cell line.
Molecular and flow cytometric Vb analysis in T-ALL samples
In addition to the 12 T-cell lines, we studied 16 TCRab1 T-ALL for
their Vb expression profile using molecular techniques and flow
cytometric analysis (Table 3). Vb-Cb RT-PCR heteroduplex analy-
sis revealed a single clonal in-frame Vb-Cb transcript in 6 of the 16
T-ALL samples. The remaining 10 samples had at least 2 clonal
Vb-Cb transcripts; in 2 cases, even 3 and 4 clonal Vb-Cb
transcripts were present, suggestive of subclone formation with a
minor clone (less than 10%) not detectable by SB (Table 3) but
readily detectable by RT-PCR. In contrast to the low frequency of
bi-allelic in-frame Vb-Cb products in T-cell lines, 6 of 10 T-ALL
samples were found to contain double in-frame Vb-Cb transcripts
(Table 3). The identified Vb-Cb products in the T-ALL represented
Vb segments from many Vb families, with a predominance of
Vb3-Cb products (n 5 5). Gene segments of the Jb1 region were
identified in 17 Vb-Cb products, whereas in 12 products, Jb2
segments could be found.
Reactivity with one of the Vb mAbs was seen in 8 of the 16
T-ALL samples. In all 8 samples, the Vb antibody reactivity pattern
was completely in line with the results of the molecular Vb
analysis, confirming the single (in-frame) transcript in most of
these 8 samples. Although samples T077 and T140 with 2 in-frame
Vb-Cb transcripts might have shown double Vb protein expres-
sion, this did not occur, as evidenced by the single Vb8 (T077) and
Vb3 (T140) membrane expression on these cells. Potential double
Vb expression in a few other cases (T012, T044, T145) remained
undetected because of the lack of the relevant Vb mAbs for both
in-frame alleles in the panel. In 8 T-ALL samples, no reactivity of
the entire T-ALL cell population with any of the Vb antibodies
from the panel was seen, despite the clear presence of a TCRab
Table 2. Vb family primers and Cb primer
Primer Sequence (59-39)
Vb1 GAA CTA AAC CTG AGC TCT CTG
Vb2 CAG CTT CTA CAT CTG CAG TGC
Vb3 CTG GAG TCC GCC AGC ACC A
Vb4 GAG CAA CAT GAG CCC TGA AG
Vb5A GCT CTG AGA TGA ATG TGA GCG CC
Vb5B GCT GAA TGT GAA CGC CTT GTT G
Vb6A ATC CAG CGC ACA CAG CAG GAG
Vb6B GAA GAT CCA GCG CAC AGA GC
Vb7A CTC ACC TGA ATG CCC CAA CAG
Vb8 GCC CTC AGA ACC CAG GGA CT
Vb9 CTG GAG CTT GGT GAC TCT GCT GT
Vb10 GAT CCA GTC CAC GGA GTC AGG
Vb11 CCT GGA GTC TGC CAG GCC CTC
Vb12 CAC TCT GGA GTC CGC TAC C
Vb13A TCA GGC TGC TGT CGG CTG CTC
Vb13B TGG GGT TGG AGT CGG CTG CTC
Vb13C TCA GGC TGG AGT CGG CTG CTC
Vb13D TCA GGC TGG AGT CAG CTG CTC
Vb13E CCT CAC GTT GGC GTC TGC TGT
Vb14 GTC TCT CGA AAA GAG AAG AGG
Vb15 CCC TAG AGT CTG CCA TCC C
Vb16 GTG CAG CCT GCA GAA CTG GAG
Vb17 CAC TGT GAC ATC GGC CCA AAA G
Vb18 GGA TCC AGC AGG TAG TGC G
Vb19A ATC CTG TCC TCA GAA CCG GGA
Vb20 CCT CCT CAG TGA CTC TGG C
Vb21 ATC CAG CCT GCA GAG CTT GG
Vb22 GAA GAT CCG GTC CAC AAA GCT G
Vb23A CTG AAC TGA ACA TGA GCT CCT T
Vb24 CAT CCG CTC ACC AGG CCT G
Vb25 TCC CAA ATT CAC CCT GTA GCC TTG
Cb AGA TCT CTG CTT CTG ATG GCT C
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molecule on the membrane. In virtually all instances, this nonreac-
tivity can most probably be attributed to expression of the Vb-Cb
product for which no Vb mAb is available (eg, Vb4 in T015 or
Vb24 in T012) or might be caused by a family member not covered
by the available Vb family antibody (eg, members of the Vb5,
Vb6, and Vb7 families). The precise members of each Vb gene
family could not be recognized in our study because the position of
our Vb primers is close to the 39 end of the segments, thereby
resulting in PCR products that do not include sufficient sequence
information for Vb member identification. Sample T139 with
in-frame Vb3-Cb and Vb11-Cb products is remarkable in that the
cells should have been recognized with either the Vb3 or the Vb11
mAb, both of which belong to a single-member gene family.
However, for reasons that remain unclear, this did not occur. One
possible explanation might be that the actual epitope in either the
Vb3 or the Vb11 chain was modified or influenced by the
junctional region or by the involved Jb segment.
Vb repertoire analysis for clonality assessment
in mature T-cell proliferations
Although the results of the Vb analysis in T-cell lines and T-ALL
samples showed that the clonal cell population could easily be
identified by Vb mAb reactivity or by lack of reactivity with any of
the Vb mAbs in the panel, the relevant diagnostic application of Vb
gene analysis in daily practice concerns the analysis of postthymic
mature lymphoproliferations of the T-cell lineage. For this reason
we chose to study the applicability of Vb repertoire analysis in a
large series of 47 mature TCRab T-cell proliferations (including
T-NHL, T-CLL, T-PLL, and T-LGL) that, in the past decade, had
been sent to our laboratory with a strong suspicion of clonality
(Table 4). All samples were indeed found to contain clonal TCRB
rearrangements in SB analysis. Next, the samples were subjected to
Vb-Cb RT-PCR, followed by heteroduplex analysis to confirm or
exclude the clonal character of the obtained RT-PCR products. This
revealed the presence of dominant clonal Vb-Cb transcripts in all
42 samples from which RNA could be isolated. In 26 cases only a
single transcript was detectable, whereas in 14 cases double Vb-Cb
products were seen (Table 4). Remarkably, in 2 samples (93-067
and 96-019), 3 dominant clonal products were apparent. SB
analysis of case 96-019 already suggested more than 2 rearranged
alleles, but in case 93-067 this was not anticipated from the SB
pattern because no additional bands were apparent. Further sequenc-
ing in the latter case revealed that the 3 PCR products contained
distinct junctional regions, excluding cross-annealing of primers as
an explanation for the occurrence of multiple bands.
To compare the molecular and flow cytometric Vb results in
these T-cell proliferations, we sequenced the Vb-Cb RT-PCR
products. Unfortunately, sequence analysis could not be performed
in the 5 samples from which RNA was lacking. In-frame Vb-Cb
transcripts were indeed identified in all 26 evaluable cases that
showed only a single RT-PCR product (Table 4). Remarkably, in
most (at least 9 of 16) sequenced cases with multiple Vb-Cb
products, more than one (distinct) in-frame Vb-Cb transcript
was found.
Table 3. Vb usage in T-cell lines and T-ALL samples as determined by molecular analysis and mAb reactivity
Sample TCRb chain
Age,
sex
SB
analysis RT-PCR 1 HD
Sequence analysis of RT-PCR products Vb MAb
reactivityAllele 1 (frame) Allele 2 (frame)
T-cell lines
CEM CyTCRb NA R/R Vb9-Cb Vb9-Jb2.3 (1) — Vb9.1
DND-41 TCRbd1 NA R/R Vb13-Cb/Vb18-Cb Vb18-Jb1.2 (1) Vb13-Jb2.7 (2) no reactivity
HPB-ALL TCRab1 NA R/R Vb5-Cb/Vb6-Cb Vb5-Jb2.5 (1) Vb6-Jb2.5 (2) Vb5.2/5.3
HSB-2 CyTCRb NA R/R Vb5-Cb Vb5-Jb1.1 (1) — Vb5.1
HUT78/H9 TCRab1 NA R/R Vb23-Cb Vb23-Jb1.2 (1) — Vb23
KT-1 TCRab1 NA R/R Vb15-Cb/Vb18-Cb Vb18-Jb2.3 (1) Vb15-Jb1.2 (1) Vb18
MOLT16/17 TCRab1 NA R/R Vb2-Cb Vb2-Jb2.3 (1) — Vb2
MOLT3/4 CyTCRb NA R/R Vb2-Cb/Vb12-Cb Vb2-Jb2.1 (1) Vb12-Jb2.5 (2) Vb2
P12 CyTCRb NA R/R Vb13-Cb Vb13-Jb2.1 (1) — Vb13.1/13.3
PF-382 CyTCRb NA R/R Vb2-Cb/Vb6-Cb Vb2-Jb2.1 (1) Vb6-Jb2.7 (2) Vb2
RPMI8402 CyTCRb NA R/R Vb17-Cb/Vb24-Cb Vb24-Jb1.5 (1) Vb17-Jb2.7 (2) no reactivity
SUP-T3 CyTCRb NA R/R Vb3-Cb Vb3-Jb2.3 (1) — Vb3
T-ALL samples
T002 TCRab1 T-ALL 5, F R/R Vb3-Cb Vb3-Jb1.5 (1) — Vb3
T010 TCRab1 T-ALL 3, M R/R Vb7-Cb Vb7-Jb1.4 (1) — no reactivity
T012 TCRab1 T-ALL 34, M R/R Vb9-Cb/Vb11-Cb/Vb23-
Cb/Vb24-Cb*
Vb11-Jb1.5 (1)/Vb24-Jb1.5 (1) Vb9-Jb2.1 (1)/Vb23-Jb1.2 (1) no reactivity
T015 TCRab1 T-ALL np, np R/R Vb4-Cb/Vb6-Cb Vb4-Jb2.1 (1) Vb6-Jb1.1 (2) no reactivity
T017 TCRab1 T-ALL 3, F R/R Vb13-Cb/Vb20-Cb Vb20-Jb1.5 (1) Vb13-Jb1.2 (2) Vb20
T020 TCRab1 T-ALL 14, np R/R Vb7-Cb/Vb21-Cb Vb21-Jb2.3 (1) Vb7-Jb2.2 (2) Vb21.3
T029 TCRab1 T-ALL 10, F R/R Vb22-Cb Vb22-Jb1.1 (1) — Vb22
T044 TCRab1 T-ALL np, np R/R Vb6-Cb/Vb21-Cb/Vb24-
Cb*
Vb6-Jb1.2 (1)/Vb21-Jb2.1 (1) Vb24-Jb1.1 (1) no reactivity
T047 TCRab1 T-ALL np, np R/R Vb2-Cb Vb2-Jb1.2 (1) — Vb2
T069 TCRab1 T-ALL 29, M R/R Vb3-Cb Vb3-Jb1.6 (1) — Vb3
T077 TCRab1 T-ALL 10, M R/R Vb3-Cb/Vb8-Cb Vb8-Jb2.1 (1) Vb3-Jb2.1 (1) Vb8
T139 TCRab1 T-ALL 14, M R/R Vb3-Cb/Vb11-Cb Vb3-Jb2.1 (1) Vb11-Jb1.1 (1) no reactivity
T140 TCRab1 T-ALL 28, M R/R Vb3-Cb/Vb6-Cb Vb3-Jb2.5 (1) Vb6-Jb1.2 (1) Vb3
T145 TCRab1 T-ALL 51, M R/R Vb5-Cb/Vb7-Cb Vb5-Jb1.5 (1) Vb7-Jb2.3 (1) no reactivity
T181 TCRab1 T-ALL np, np R/R Vb7-Cb Vb7-Jb2.1 (1) — no reactivity
T182 TCRab1 T-ALL np, np R/R Vb6-Cb/Vb13-Cb Vb6-Jb1.1 (1)† Vb13-Jb2.5 (2) no reactivity
*Multiple Vb-Cb products probably resulting from subclone formation with one major clone and one minor clone (, 10%) not detectable by SB analysis.
†Transcript involves Cb2 segment coupled to the Jb1.1 segment of the VDJ exon, which fits with deletion as seen in SB analysis. np indicates not provided.
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Table 4. Vb analysis for clonality assessment in mature T-cell proliferations
Sample Immunophenotype Diagnosis
Age,
sex WBC*
% of
MNC†
SB
analysis RT-PCR 1 HD
Sequence analysis of RT2PCR
products Vb
sum
Vb reactivity of
cloneAllele 1 (frame) Allele 2 (frame)
85-002 CD3/4/2/5 T-PLL 66, F ND 95% R/R Vb13-Cb Vb13-Jb2.5 (1) — #5% no reactivity
86-041 CD3/8/2/5/7 T-LGL 58, F 24.9 95% R/R Vb1-Cb/Vb7-Cb Vb1-Jb2.1 (1) Vb7-Jb1.2 (1) 93% Vb1 (90%)
89-068 CD3/4/8/2/7/16neg/56/57 T-LGL 56, M 50.8 55% R/R Vb2-Cb/Vb7-Cb Vb2-Jb2.7 (1) Vb7-Jb1.1 (1) 90% Vb2 (60%)
90-008 CD3/4/2/7/16neg/56/57 T-LGL 58, M 10.6 85% R/R Vb6-Cb Vb6-Jb2.7 (1) — 13% no reactivity
91-004 CD3/8/2/7/16neg/56neg T-CLL 85, F 4.7 90% R/R Vb5-Cb/Vb6-Cb Vb5-Jb2.1 (1) Vb6-Jb1.1 (1) 8% no reactivity
91-010 CD3/8/2/7/16/57p T-LGL 46, F 7.7 60% R/R Vb14-Cb Vb14-Jb1.2 (1) — 99% Vb14 (99%)
91-030 CD3/4/2/5/7/56neg57neg MF/SS 67, M 13.4 60% R/R Vb5-Cb Vb5-Jb2.7 (1) — 67% Vb5.2/5.3 (24%) 1
Vb22 (10%)3
92-024 CD3/8/2/5/7/57p T-LGL 55, F 11.3 80% R/R Vb7-Cb Vb7-Jb1.5 (1) — 97% Vb7.1 (85%)
92-050 CD3/8/2/5/7/57 T-LGL 50, M 7.0 80% R/R Vb23-Cb Vb23-Jb1.5 (1) — 95% Vb23 (85%)
93-005 CD3/4/2/5/7 T-PLL 75, M 414 98% R/R Vb3-Cb Vb3-Jb2.1 (1) — 98% Vb3 (94%)
93-026 CD3/8/2/5/7/16neg/
56neg/57p
T-LGL 66, M 6.5 66% R/G Vb6-Cb Vb6-Jb2.7 (1) — #5% no reactivity
93-027 CD3/8/5/7/57p T-LGL 53, M ND 80% R/R Vb8-Cb Vb8-Jb2.5 (1) — 98% Vb8.1/8.2 (90%)
93-067 CD3/4/8/2/7/57p T-LGL 53, M 6.1 60% R/R Vb3-Cb/Vb8-Cb/
Vb13-Cb
Vb13-Jb1.1 (1) Vb3-Jb2.1 (1)/
Vb8-Jb1.5 (1)
90% Vb13.1/13.3 (67%)
93-074 CD3/4/8/5/7 T-CLL 68, F 15.6 25% R/R Vb13-Cb Vb13-Jb1.1 (1) — #5% no reactivity
94-058 CD3/4/2/5/7/56neg/57neg T-CLL 84, np 14.8 65% R/R Vb13-Cb Vb13-Jb2.2 (1) — 17% no reactivity
95-082 CD3/4/2/5/56neg/57neg SS 50, M 63.2 60% R/G Vb12-Cb Vb12-Jb1.1 (1) — 97% Vb12.2 (65%)
95-121 CD3/4/8p/16p/56p/57p T-LGL 75, M 11.8 60% R/G 1
R/R
Vb6-Cb/Vb13-Cb Vb6-Jb2.3 (1) Vb13-Jb1.1 (1) 89% Vb13.1/3 (60%) 1
Vb6.7 (16%)
95-123 CD3/4/8p/5/7/56neg/57neg T-NHL np, M 123 90% R/R Vb8-Cb Vb8-Jb1.2 (1) — 98% Vb8.1/8.2 (89%)
95-128 Cd3/4/2/5/7 T-CLL np, np ND 80% R/R Vb2-Cb Vb2-Jb2.3 (1) — 89% Vb2 (81%)
95-134 CD3/4/2/5/7 T-PLL np, np ND 75% R/R Vb8-Cb Vb8-Jb2.1 (1) — 96% Vb8.1/8.2 (92%)
95-140 CD3/4/5/7/16neg/56neg/
57neg
SS 61, M 97.4 83% R/R Vb5-Cb/Vb13-Cb Vb13-Jb2.7 (1) Vb5-Jb2.5 (2) #5% no reactivity
96-013 CD3/8/2/16/57p T-LGL 58, F 14.3 90% R/R Vb12-Cb Vb12-Jb2.2 (1) — 98% Vb12.2 (95%)
96-019 CD3/8/2/5/7/57p T-LGL 62, M 7.7 35% R/G 1
R/R
Vb7-Cb/Vb9-Cb/
Vb13-Cb
Vb7-Jb1.2 (1) Vb9-Jb2.1 (1)/
Vb13-Jb2.1 (1)
12% no reactivity
96-020 CD3/8/2/5/57p T-LGL 63, M 6.1 70% R/R Vb5-Cb/Vb23-Cb Vb23-Jb1.4 (1) Vb5-Jb1.1 (2) 95% Vb23 (85%)
96-042 CD3/4p/8p/7/56p/57p T-LGL 45, M 5.5 25% R/R Vb15-Cb/Vb16-Cb Vb16-Jb2.1 (1) Vb15-Jb2.1 (1) 82% Vb16 (31%)
96-043 CD3/8/2/5/7/16p/57p T-LGL 73, F 11.1 85% R/R Vb22-Cb Vb22-Jb2.6 (1) — 95% Vb22 (90%)
96-049 CD3/4/2/5/7/16neg/
56neg/57neg
T-CLL 71, M 32.4 85% R/G Vb22-Cb Vb22-Jb1.1 (1) — 95% Vb22 (94%)
96-050 CD3/8/16/57p T-LGL 52, F 9.5 15% R/R Vb3-Cb/Vb22-Cb Vb3-Jb1.2 (1) ND 83% Vb3 (20%)
96-067 CD3/8/2/5/16p/57p T-LGL 39, F 9.0 70% R/R Vb6-Cb/Vb19-Cb Vb6-Jb2.1 (1) Vb19-Jb2.3 (2) 20% no reactivity
96-154 ND T-CLL 49, F 6.9 50% R/R Vb7-Cb/Vb21-Cb Vb7-Jb2.5 (1) ND 8% no reactivity
97-064 CD3/4p/8p/57p T-LGL 71, M 1.8 70% R/R Vb13-Cb Vb13-Jb2.7 (1) — 14% no reactivity
97-086 CD3/4/8/57p T-LGL 45, F 2.2 40% R/R Vb6-Cb Vb6-Jb2.2 (1) — 97%§ Vb6.1 (97%)
97-089 CD3/4/2/5/7 T-PLL 57, M 450 90% R/R Vb7-Cb/Vb9-Cb Vb7-Jb2.6 (1) Vb9-Jb2.5 (1) 10% no reactivity
97-121 CD3/4/2/5/7 T-NHL 49, F 32.3 80% R/R Vb11-Cb/Vb14-Cb Vb14-Jb2.5 (1) ND 97% Vb14 (93%)
98-002 CD3/4/5/7/16neg/
56neg/57neg
T-CLL 83, F 59.0 80% D/R Vb7-Cb Vb7-Jb1.4 (1) — #5% no reactivity
98-040 CD3/4/2/5/7neg T-AILD 68, F 18.0 40% R/R ND ND ND 85% Vb17 (53%)
98-047 CD3/4/8/5/7/16neg/
56neg/57neg
T-CLL 67, M 82.0 95% R/R ND ND ND 99% Vb13.1/13.3 (98%)
98-072 CD3/4/8/2/16neg/
56neg/57neg
T-CLL 60, M 210 95% R/R ND ND ND 99% Vb2 (99%)
98-080 CD3/4p/2/5/7/16neg/
56neg/57neg
T-PLL 77, M NA(LN) 80% R/R ND ND ND #5% no reactivity
98-086 CD3/4/5/7/16neg/
56neg/57neg
T-CLL 71, M 158 88% R/G Vb3-Cb Vb3-Jb1.2 (1) — 99% Vb3 (99%)
98-090 CD3/4/2/5/7 T-PLL 62, F 522 95% R/R Vb1-Cb/Vb23-Cb Vb1-Jb2.3 (1) ND 99% Vb1 (99%)
98-126 CD3/8/2/16/56/57p T-LGL 73, M 3.3 45% R/R Vb2-Cb Vb2-Jb1.3 (1) — 98% Vb2 (53%)
98-194 CD3/8/2/7/16-56/57neg T-LGL 38, F 10.1 90% R/R Vb6-Cb/Vb12-Cb Vb6-Jb1.1 (1) Vb12-Jb2.3 (1) #5% no reactivity
99-100 CD3/8/2/7/16/57 T-LGL 49, M 7.6 75% R/G Vb17-Cb Vb17-Jb2.7 (1) — 80% Vb17 (66%)
99-125 CD3/8/2/5/7/56neg/57neg T-PLL 41, M 174 98% R/R Vb3-Cb Vb3-Jb2.4 (1) — 99% Vb3 (99%)
99-211 CD3/8/2/5/7/16neg/
56neg/57p
T-LGL 72, F 2.1 85% R/R ND ND ND 96% Vb2 (92%)
99-256 CD3/4/2/5p/7p/16neg/
56neg/57neg
T-CLL 69, M 17.0 95% R/R Vb13-Cb Vb13-Jb1.2 (1) — #5% no reactivity
*WBC given in 109/L.
†Aberrant cell clone presented as percentage MNC fraction.
‡Second population probably represents a polyclonal proliferation or a small subclone.
§Percentage of CD41/CD81 T-cell population.
np indicates not provided; p, partial reactivity.
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Flow cytometric analysis of the Vb repertoire was performed in
all 47 cases. Most of the studied samples (n 5 31) appeared to have
a restricted Vb reactivity pattern, with predominance of a single
Vb mAb reactivity (exemplified in Figure 1). Although this
restricted reactivity concerned many different Vb specificities,
Vb2 (n 5 5) and Vb3 (n 5 4) were observed more frequently than
others. The latter may not be too surprising given the relatively
high frequency of, especially, Vb21 TCRab cells in healthy
controls (Table 1 contains median values).10 In the other 16 cases,
the complete lack of reactivity of the suspect leukemic cell
population with any of the individual Vb mAbs or the 6 Vb
mixtures of the panel10 was considered indirect evidence for the
“clonal” character of these cells (Figure 2).
Comparison of the data from molecular and flow cytometric
analyses revealed complete concordance between the identified
in-frame Vb-Cb transcript and the expressed Vb domain of the
TCRb chain in 26 cases (Table 4). Remarkably, in case 95-121, we
identified Vb6.7- and Vb13.1/13.3-positive cells, which is in line
with the presence of the corresponding in-frame Vb-Cb transcripts
in this sample and the presence of 2 clones as found by SB analysis
and immunophenotyping. In addition, in sample 91-030, 2 popula-
tions (Vb5.2/5.3 and Vb22) were found, but here no clear evidence
was detected for further immunophenotypical heterogeneity or for
clonal Vb22-Cb transcripts, suggesting that the Vb22-positive
population concerned either a small subclone or a polyclonal
Vb221 cell population. The latter is more likely because a
monoclonal subclone of 10% Vb221 T-cells should have been
identified in PCR heteroduplex analysis; in contrast, only poly-
clonal (heteroduplex) Vb22-Cb PCR products were observed in
sample 91-030.
In 16 cases no single Vb reactivity of the clonal cell population
was observed, despite the presence of clonal Vb-Cb RT-PCR
products in 15 of these samples (one was not studied through
RT-PCR). Close examination revealed that in all 15 cases, the
clonal transcripts contained gene segments derived from multimem-
ber Vb families (Vb5, Vb6, Vb7, and Vb13) known to be
incompletely covered by the respective mAbs in the current panel.
The position of the various primers for these Vb families of gene
segments, however, did not allow for a detailed analysis into the
exact gene member that was used. Nevertheless, even in these cases
without Vb mAb reactivity, the molecular and flow cytometric
results were not discordant.
Vb oligoclonality in mature T-cell proliferations
Although in all analyzed mature T-cell proliferations 1 or 2
dominant Vb-Cb RT-PCR products could be identified, in several
samples a whole array of additional Vb-Cb products of variable,
but mostly weak, intensity were found, next to the dominant clonal
Figure 1. Flow cytometric Vb analysis in patients with mature T-cell prolifera-
tions compared with healthy controls. Using Vb8.1/8.2, Vb13.1/13.3, and Vb22
(FITC-labeled) double immunofluorescence stainings with CD3-PerCP, only small
percentages of CD31/Vb1 cells can be identified in healthy controls (upper panel),
whereas similar double stainings in samples 93-027, 93-067, and 96-049 enable
identification of large T-cell populations with single Vb8.1/8.2, Vb13.1/13.3, and Vb22
expression, respectively (lower panel).
Figure 2. Flow cytometric Vb repertoire analysis using Vb mAb mixtures in
mature T-cell proliferation patients. (A) In healthy controls, 60% to 65% of
CD31 cells are recognized in double immunofluorescence stainings with 6
different Vb mAbs mixtures in combination with CD3-PerCP.10 (B) Using compa-
rable stainings in T-CLL patient 98-086, 99% of CD31 cells are recognized by Vb
mAbs mix 1, whereas all other 5 mixes only recognize less than 1% of all CD31
cells. This indicates the presence of a large, presumably clonal CD31 T-cell
population with single Vb expression. (C) Double immunofluorescence stainings
with the 6 Vb mAbs mixtures resulted in less than 5% CD31/Vb1 cells in T-CLL
patient 98-002, suggesting the presence of a large, presumably clonal CD31
T-cell population with single Vb expression not recognized by any of the Vb mAbs
in the current panel.
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Vb-Cb product(s), as exemplified in Figure 3. Close examination
of these oligoclonal samples disclosed that virtually all were
diagnosed as T-LGL leukemias, whereas only a few concerned
patients with T-CLL or Se´zary syndrome. Despite their oligoclonal
character, in all cases a dominant clonal cell population was
observed, as evidenced by the flow cytometric data.
Discussion
Vb repertoire analysis for identification of clonal
cell populations
Clonality assessment of mature T-cell proliferations has long
been performed by means of SB analysis. Although SB analysis
is highly reliable owing to an almost complete lack of false-
positive and false-negative results, it is time consuming and
labor intensive, and it requires relatively large amounts of
high-quality DNA. The latter is generally unavailable in paraffin-
embedded tissues or small tissue biopsies. For this reason, PCR
analysis of TCRG gene rearrangements has been used as an
alternative strategy.15-17 However, the relatively restricted diver-
sity of TCRG gene rearrangements and the resultant high-
background amplification of similar rearrangements in normal T
cells limits the potential of this approach. Because the TCRB
recombination diversity is essentially larger than that of TCRG
genes, analysis of the Vb repertoire of TCRB genes has been put
forward as a diagnostic strategy for clonality studies in suspect
T-cell proliferations. This approach can also be used to study the
actual TCRB repertoire in other disease states with high T-cell
activity, such as autoimmune diseases,18-22 immunodeficien-
cies,23-25 and alloreactivity in patients who have undergone
transplantation.26-28 Until recently, this type of analysis mainly
concerned PCR-based assays.18,21,22,26,29,30 However, a much
faster and more quantitative analysis of the TCRb repertoire is
now possible through the use of mAbs directed against the Vb
domains of TCRab molecules, which cover 65% to 70% of Vb
domains in blood T lymphocytes of children and adults.10,31-34
We performed parallel molecular and flow cytometric Vb
analyses in a series of SB-defined TCRab T-ALL samples and
T-cell lines to validate both approaches for the detection of
clonality. Indeed, clonal Vb-Cb transcripts could easily be detected
in all T-ALL samples and T-cell lines. Moreover, the corresponding
Vb mAb reactivity patterns also indicated the presence of large,
single Vb domain (“clonal”) cell populations in these cases,
indicating that both methods are suitable for detecting aberrant
T-cell proliferations. However, patients with T-ALL generally do
not have diagnostic dilemmas for which Vb analysis is required
because thymus derived T-ALL is relatively easy to diagnose using
mAbs against the nuclear enzyme TdT and various CD antigens.
Given that the main diagnostic problems generally concern suspect
mature (postthymic) T-cell proliferations, we studied a series of 47
such mature T-cell proliferations, proven to be clonal based on SB
analysis. RT-PCR heteroduplex analysis of Vb-Cb transcripts in all
42 analyzed cases confirmed the (mono)clonal character of the
studied cell samples. Flow cytometric Vb repertoire analysis of the
suspect mature T-cell proliferations identified single Vb domain
expression in 31 (66%) of 47 cases. Together with the single Vb
reactivity in 10 of 12 T-cell lines and in 8 of 16 T-ALL samples, this
means that 49 (65%) of 75 cases were picked up through flow
cytometric Vb repertoire analysis. In 16 of the 47 cases showing
extensive T-cell proliferation, the combined Vb antibody reactivity
covered less than 20% of all CD31 T cells (instead of approxi-
mately 65%), which is indirect proof for the presence of a large
T-cell population with single, though unidentified, Vb domain
expression (Table 4).
Flow cytometric Vb repertoire analysis can thus be used as a
(quantitative) screening method for the detection of large, aberrant
T-cell populations with single Vb domain expression. To define
single Vb expression, the mean normal Vb values should be used,
also taking into account the differences in the use of particular Vb
domains between CD41 and CD81 T-cell populations and observa-
tions of a more restricted Vb usage of especially CD8 T lympho-
cytes in the elderly.10,35-39 Taken together, this means that we
consider T-cell expansions aberrant if they concern more than the
mean Vb value plus 3 SD (generally more than 20%) of the
peripheral blood T cells or if the suspect population exceeds
2.0 3 109/L. The arbitrary cut-off of 2.0 3 109/L is considered an
important criterion for diagnosing T-cell LGL leukemia,40 though
even lower absolute counts might sometimes occur. Use of a 6-tube
test kit with Vb mAbs mixtures, each covering maximally 10% to
15% of the Vb repertoire (Figure 2), further enables the screening
for Vb repertoire restrictions.10 Meanwhile, an attractive commer-
cial 8-tube kit (IO Test Beta Mark) has become available (Immuno-
tech/Beckman Coulter, Marseilles, France); in each of the 8 tubes,
3 distinctly labeled Vb antibodies are present that not only allow
detection of single Vb expression but also direct identification of
the involved Vb domain or family.
The results in this study suggest that detection of a T-cell
population with restricted Vb usage in principle implies clonality
of the involved proliferation. The fact that detection of single Vb
expression is not necessarily equal to clonality is illustrated by, for
example, case 91-030 showing a small Vb221 population of
approximately 10% that was not found to be clonal in molecular
analysis. Although this expanded Vb221 population was smaller
than 20%, we think that in doubtful cases it generally remains
important to confirm the presumed clonality by amplification of the
Figure 3. Vb-Cb RT-PCR heteroduplex analysis. After
reverse transcription of total RNA of T-LGL patient 86-
041, cDNA was PCR amplified using Vb family primers in
combination with a Cb primer. On heteroduplex analysis,
2 major clonal products (Vb1-Cb and Vb7-Cb) belonging
to the dominant clone were observed in addition to
several weaker clonal Vb-Cb products. These latter
products represented rearranged alleles of small sub-
clones that were not identified with flow cytometric
Vb analysis.
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involved Vb-Cb product. In case of large Vb unreactive T-cell
populations, the clonal character should be established by PCR
using a complete set of Vb family primers or by other molecular
approaches, such as PCR analysis of TCRG genes or SB analysis of
TCRB genes. The detection limits of both Southern blot analysis
(5%-10%) and PCR-based assays (1%-5%) are superior over flow
cytometric analysis of the Vb repertoire, which has a sensitivity of
20% for single Vb domain expression because of the background
of normal Vb usage. Nevertheless, this sensitivity of the latter
method might be improved if additional immunophenotypic mark-
ers are included to detect Vb usage in combination with a specific
T-cell phenotype such as CD4, CD8, CD56, and CD57.1
Finally, a major advantage of flow cytometric Vb analysis over
PCR-based assays is that once established and confirmed, the
Vb-restricted T-cell population can easily and quantitatively be
monitored in combination with other markers during and after
therapy, using age-dependent reference values for comparison.10,41
Oligoclonality of T-LGL proliferations
During analysis of the mature T-cell proliferations, we observed
that especially in many T-LGL samples, multiple weak additional
products were seen next to 1 or 2 Vb-Cb transcripts belonging to
the immunophenotypically dominant clone. Limited sequencing of
these clonal products did not show similar Vb gene segments or
junctional region sequences. This observation provides further
evidence for the hypothesis raised earlier, which is that T-LGL
derive from polyclonal or oligoclonal proliferations of antigen-
activated cytotoxic T-cells and that, in some situations, transforma-
tion or dysregulation of growth or apoptosis results in T-LGL leukemia
showing a more restricted and dominant Vb usage (expressed as
percentage MNCs) and a raised absolute cell count of abnormal
cells.42-45 Furthermore, the generally indolent course of this type of
T-cell proliferation and the relatively lower white blood cell counts
(compared to T-CLL and T-PLL proliferations) are also in line with a
pretransformation state of oligoclonal proliferations of activated T-cells.
Monoreactivity in T-ALL and mature T-cell populations
Remarkably, in many T-ALL (6 of 10) and mature T-cell prolifera-
tions (at least 9 of 16) with bi-allelic TCRB gene rearrangements
and, to a lesser extent, in T-cell lines (1 of 6 cases), double in-frame
transcripts were observed. In theory this could lead to double Vb
expression in particular samples. However, in virtually all cases
that could be evaluated, the clonal T-cell population reacted with
only one of the Vb mAbs; monoreactivity cannot be proven
formally in a few samples because of the lack of appropriate Vb
antibodies in the panel. In case 95-121, the 2 identified in-frame
Vb-Cb transcripts appeared to be derived from 2 distinct T-cell
populations, given the results of flow cytometric analysis. Taken
together, the data strongly suggest that in cases with double
in-frame Vb-Cb products, monospecificity of the TCR is guaran-
teed by regulation at the level of translation of TCRb chains or by
preferential pairing of one TCRb chain with the involved
TCRa chain.
We conclude from our data that flow cytometric Vb repertoire
analysis is a fast and relatively cheap alternative tool that can be
used as a powerful screening method in patients with suspect T-cell
proliferations. Formally, however, clonality as deduced from single
Vb domain expression (more than 20% of cells) or from the lack of
reactivity of a large (more than 50% to 60%) TCRab1 T-cell
population would still need proof by molecular assays. Neverthe-
less, flow cytometric analysis has the additional advantages of
looking within T-cell subsets and precise quantitation of the Vb1
cells. An additional interesting application is the flow cytometric
monitoring of Vb1 leukemic cells during and after therapy, once a
single Vb expression has been determined.
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